Skip to main content
. 2020 Apr 21;64(5):e02313-19. doi: 10.1128/AAC.02313-19

TABLE 7.

CZA monotherapy MIC increase and emergence of resistancea

Initial infection MIC (mg/liter) Recurrent infection MIC (mg/liter) Emergence of resistance? Duration of CZA (days) Source of infection Baseline RRT?
0.25 0.75 No 10.6 Intra-abdominal No
0.75 1.5 No 7.6 Respiratory No
0.75 12 Yes 10.3 Respiratory Yes
4 12 Yes 13.2 Respiratory Yes
2 32 Yes 4.4 Respiratory Yes
a

CZA, ceftazidime-avibactam; RRT, renal replacement therapy.